WG
ADCT icon

Winton Group’s ADC Therapeutics ADCT Stock Holding History

Winton Group’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-165,601
Closed -$5.3M – 1361
2020
Q4 		$5.3M Sell
165,601
-64,100
-28% -$2.1M 0.38% 19
2020
Q3 		$2.6M Buy
229,701
+701
+0.3% +$30.3K 0.08% 410
2020
Q2 		$10.7M Buy
+229,000
New +$8.69M 0.28% 34

Other funds holding ADCT

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
GH
Grosvenor Holdings Chicago, Illinois $512M AUM 19.57% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
MICM
Matthews International Capital Management San Francisco, California $246M AUM 10.45% 1-Year Est. Return

Winton Group's ADCT Position: Q1 2021 in Review

Winton Group sold out of ADC Therapeutics (ADCT) in Q1 2021, closing a stake of 165,601 shares — an estimated $5.3M sold.

Winton Group first reported a position in ADCT in Q2 2020 and held it in 3 quarters. The position peaked at $10.7M in Q2 2020. 59 funds tracked by Wall St. Rank hold ADCT as of Q1 2021.

  • Winton Group reported no remaining ADC Therapeutics position as of Q1 2021 after selling out during the quarter.
  • Winton Group sold 165,601 ADC Therapeutics shares in Q1 2021, an estimated $5.3M.
  • Winton Group first reported a position in ADC Therapeutics in Q2 2020 and held it in 3 quarters.
  • Winton Group's ADC Therapeutics position peaked at $10.7M in Q2 2020.
  • 59 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2021.

Based on Winton Group's 13F filing for Q1 2021, filed 21 Jul 2021.